🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepat...
Status
Not Yet Recruiting
Location
Zhejiang Cancer Hospital
Start Date
2027-09-01
Trial ID
NCT07691645
Treatments Being Tested
Hepatic artery infusion chemotherapy (HAIC) has shown promising outcomes in...
Status
Unknown
Location
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,
Start Date
2022-10-16
Trial ID
NCT05573282
Treatments Being Tested
This is a multicenter, randomized, controlled, phase II study to evaluate t...
Status
Unknown
Location
Shanghai Zhongshan Hospital
Start Date
2022-07-13
Trial ID
NCT05278351
Treatments Being Tested
This is a multicenter, open-label, prospective, randomized controlled Phase...
Status
Recruiting
Location
Beijing Friendship Hospital, Capital Medical University
Start Date
2025-02-11
Trial ID
NCT06829355
Treatments Being Tested
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-sta...
Status
Withdrawn
Location
Multiple Locations
Start Date
2023-04-30
Trial ID
NCT05582031
Treatments Being Tested
Combination of anti-angiogenic molecular targeted therapy and anti- program...
Status
Unknown
Location
National Taiwan University Hospital
Start Date
2020-12-16
Trial ID
NCT04183088
This retrospective cohort study collected data of patients with huge hepato...
Status
Completed
Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Start Date
2018-06-01
Trial ID
NCT07639294
This is an open-label, multicenter, randomized controlled Phase II trial. P...
Status
Not Yet Recruiting
Location
West China Hospital
Start Date
2026-03-05
Trial ID
NCT07463248
Treatments Being Tested
To evaluate the effectiveness of TACE combined with immunotherapy and targe...
Status
Unknown
Location
the Qianfoshan Hospital
Start Date
2024-01-01
Trial ID
NCT06205732
Treatments Being Tested
Tislelizumab is an anti-PD-1 monoclonal antibody with high binding affinity...
Status
Unknown
Location
Beijing Cancer Hospital
Start Date
2023-05-30
Trial ID
NCT05877001
Treatments Being Tested